Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
BMC Cancer|February 7, 2018
Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancerPeter J Klauck, Stacey M Bagby, Anna Capasso, et al.
Oncogene|March 3, 2015
Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancerR K Bikkavilli, S Avasarala, M Van Scoyk, et al.
Molecular Cancer Therapeutics|October 7, 2010
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancerJohn J Tentler, Sujatha Nallapareddy, Aik Choon Tan, et al.
Oncotarget|April 13, 2016
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistanceKevin S Quackenbush, Stacey Bagby, Wai Meng Tai, et al.
British Journal of Cancer|July 23, 2013
Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant modelJ J Arcaroli, K S Quackenbush, A Purkey, et al.
Oncotarget|January 18, 2018
The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapyJustin Greene, Anna Nguyen, Stacey M Bagby, et al.
Frontiers in Pharmacology|April 2, 2013
Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer modelsTodd M Pitts, Gillian N Kulikowski, Aik-Choon Tan, et al.
Plos One|April 10, 2024
Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL)Hayley J Hawkins, Betelehem W Yacob, Monica E Brown, et al.
Frontiers in Pharmacology|July 3, 2015
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer modelsS Lindsey Davis, Kelli M Robertson, Todd M Pitts, et al.
Frontiers in Oncology|April 16, 2026
Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer modelRobert W Lentz, Adrian T A Dominguez, Nicole Baranda Balmaceda, et al.
Pageof 5